UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
Sleep 'regenerates brain support cells'
Date: Sep-04-2013It goes without saying that we all need a good night's sleep to feel re-energized for the day ahead. But now, researchers have found that sleep also helps to boost reproduction of the cells involved in brain repair. Scientists from the University of Wisconsin, Madison, have discovered that sleep increases the reproduction of cells that form myelin - the insulating material found on nerve cell projections in the brain and spinal cord. Previous studies over the years have shown that numerous genes are switched on as we sleep and switched off during wakefulness...
Transparent skull implant provides 'window to the brain'
Date: Sep-04-2013Scientists have created a novel transparent skull implant, which may give neurosurgeons a "window to the brain," according to a study published in the journal Nanomedicine: Nanotechnology, Biology and Medicine. Researchers from the University of California, Riverside, say they hope the implant will lead to new treatment strategies for those with life-threatening neurological disorders, such as traumatic brain injury and brain cancer. At present, the majority of neurological procedures involve craniectomies...
Middle-aged women with asthma at higher risk of hospitalization
Date: Sep-04-2013Women with asthma in their 40s and 50s are twice as likely to be hospitalized from the respiratory disorder, compared with men in the same age group. This is according to a study published in the journal Annals of Allergy, Asthma and Immunology. Researchers from the New York Downtown Hospital analyzed data for asthmatic men and women from the National Inpatient Sample databases between 2000 and 2010. The information was used to calculate the ratio of female to male hospitalization rates resulting from asthma throughout different age groups...
Childhood leukemia can be inherited, gene study shows
Date: Sep-04-2013Scientists say they have discovered two genetic variants, which show that both susceptibility and survival of childhood leukemia can be inherited, according to a study published in the journal Blood. Researchers from The Institute of Cancer Research in London say the discovery could lead to new drugs for children who do not respond well to current treatments for the disease. Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children and teens, occurring when the bone marrow makes too many immature lymphocytes - a type of white blood cell...
Chronically ill struggle to put food on the table
Date: Sep-04-2013A new study from Canada suggests households where adults have chronic illnesses, such as diabetes, arthritis, migraines, back problems, heart disease and mental illness, are more likely to struggle to put food on the table. And the more illnesses the adults have, the more severe the level of food insecurity in their households. Researchers from the Universities of Toronto and Calgary came to this conclusion after analyzing survey data on over 77,000 people aged 18 to 64 living in Canada. They report their findings in the online issue of the Journal of Nutrition...
Old cancer drug prevents transplant rejection
Date: Sep-04-2013New research from Sweden, published in the journal PLOS ONE, suggests that an old cancer drug may prevent immune rejection of transplanted donor tissue or organs. The discovery could lead to new treatments for autoimmune diseases - like rheumatoid arthritis or type 1 diabetes - where the person's own immune system attacks the body. The researchers, Senior Professor of Neurosurgery Leif Salford and colleagues from Lund University, were studying the effects of an old tumor drug, Zebularine, that was developed in the US in the 1960s...
Remember to weigh up risks and benefits of new PBS-listed anticoagulants
Date: Sep-04-2013NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 - and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose. These medicines will be subsidised by the Pharmaceutical Benefits Scheme (PBS) for preventing stroke in people with non-valvular atrial fibrillation, and may offer alternatives for some people...
Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313 in tuberculosis
Date: Sep-04-2013Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England. This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio's IMX313...
Novartis receives EU approval for Ilaris® in active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Date: Sep-04-2013Novartis announced today that the European Commission (EC) has approved the use of Ilaris® (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older, who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. SJIA is a rare and disabling form of childhood arthritis with limited treatment options[2]. The condition is characterized by spiking fever, rash and arthritis that can affect children as young as 2 years old and can continue into adulthood[2],[3]...
Apitope announces positive results from clinical trial of ATX-MS-1467 in relapsing multiple sclerosis
Date: Sep-04-2013Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, has announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group...
Stay Connected
